Nxtg.Ta
NXTG.TA is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and therapies.
Business. NXTG.TA is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NXTG.TA is a biotechnology company engaged in pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotech products and therapies.
NXTG.TA's capital structure is highly leveraged, with total liabilities of 5.87 million ILS and total equity of -5.52 million ILS, indicating a negative net worth. The company's liquidity position is weak, as evidenced by a current ratio of 0.05 and zero cash and equivalents. The negative free cash flow of -3.37 million ILS further exacerbates liquidity concerns.
Profitability metrics are severely negative, with an operating loss of 3.44 million ILS and a net loss of 3.28 million ILS. The return on assets is -9.30%, and the return on equity is 59.51%, which is misleading due to the negative equity base. These figures indicate a company that is not generating returns and is incurring significant losses.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided. There is no geographic revenue distribution data available, making it difficult to assess exposure to different markets. The lack of diversification increases business risk.
Growth trajectory is not evident from the data, as the company is currently experiencing a significant decline in financial performance. The operating cash flow is negative at -0.795 million ILS, and the free cash flow is -3.37 million ILS, indicating a lack of operational cash generation. There is no indication of future revenue growth or improvement in financial metrics.
The company faces significant liquidity and solvency risks, with a negative net worth and no cash reserves. The debt-to-equity ratio is -0.04, which is unusual and suggests a highly leveraged position. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the overall financial instability remains a concern.
Recent events and filings do not provide specific details on the company's operations or financial strategy. The lack of detailed information in the financial snapshot and the absence of recent events or transcripts suggest limited transparency and disclosure.
- NXTG.TA is a biotechnology company with a negative net worth and significant operating losses.
- The company's liquidity position is weak, with no cash reserves and a current ratio of 0.05.
- Profitability metrics are severely negative, with a return on assets of -9.30% and a misleadingly high return on equity due to negative equity.
- The company's financial performance indicates a lack of operational cash generation and a high risk of insolvency.
- There is limited transparency and disclosure regarding the company's operations and financial strategy.
- "margin_outlook_rationale": "The company's operating and net margins are negative, indicating a lack of profitability and potential for margin improvement.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- NXTG.TA Market data — financials · 2026-05-28